Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.53 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.53 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.53 |
| ▸ | FABP1 | P07148 | 1/20 | 0.52 |
| ▸ | FABP6 | P51161 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.48 |
| ▸ | ITGAV | P06756 | 2/20 | 0.48 |
| ▸ | FDPS | P14324 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30084988 | 1.00 | CYP1A2 (0.58) | CYP1A2CYP2C19CXCR4NUDT1KDM4D | |
| SCHEMBL19874499 | 0.98 | CYP1A2 (0.56) | CYP1A2CYP2C19CXCR4NUDT1KDM4D | |
| SCHEMBL6302675 | 0.94 | CYP1A2 (0.56) | CYP1A2CYP2C19CXCR4NUDT1KDM4D | |
| SCHEMBL6301834 | 0.93 | CYP1A2 (0.54) | CYP1A2CYP2C19CXCR4NUDT1KDM4D | |
| SCHEMBL245224 | 0.88 | CYP1A2 (0.61) | CYP1A2CYP2C19CXCR4FABP1FABP6 | |
| SCHEMBL10861718 | 0.88 | CYP1A2 (0.66) | CYP1A2CYP2C19CXCR4FABP1FABP6 | |
| Hydrochloric Acid SCHEMBL5175818 | 0.86 | CYP1A2 (0.59) | CYP1A2CYP2C19CXCR4FABP1FABP6 | |
| Hydrochloric Acid SCHEMBL5175930 | 0.86 | CYP1A2 (0.59) | CYP1A2CYP2C19CXCR4FABP1FABP6 | |
| SCHEMBL9644591 | 0.86 | CYP1A2 (0.63) | CYP1A2CYP2C19CXCR4FABP1FABP6 | |
| SCHEMBL10858528 | 0.86 | CYP1A2 (0.63) | CYP1A2CYP2C19CXCR4FABP1FABP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220378744-A1 | COMPOUNDS FOR TREATING PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) MEDIATED DISEASES OR CONDITIONS | MEDIPURE PHARMACEUTICALS INC (CA) | 2022-12-01 | — | — | US | disclosed |
| WO-2022221960-A1 | COMPOUNDS FOR TREATING PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) MEDIATED DISEASES OR CONDITIONS | Medipure Pharmaceuticals Inc. (CA) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022221960-A1 | COMPOUNDS FOR TREATING PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) MEDIATED DISEASES OR CONDITIONS | Medipure Pharmaceuticals Inc. (CA) | 2022-10-27 | — | — | WO | disclosed |
| US-20210069337-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2021-03-11 | — | — | US | disclosed |
| US-20180244698-A1 | AMINE-BORANES BEARING BORANE-INTOLERANT FUNCTIONALITIES | PURDUE RESEARCH FOUNDATION (US) | 2018-08-30 | — | — | US | disclosed |
| US-9988402-B2 | Amine-boranes bearing borane-intolerant functionalities | PURDUE RESEARCH FOUNDATION (US) | 2018-06-05 | — | — | US | disclosed |
| US-9988402-B2 | Amine-boranes bearing borane-intolerant functionalities | PURDUE RESEARCH FOUNDATION (US) | 2018-06-05 | — | — | US | disclosed |
| US-20180076403-A1 | AMINE-BORANES AS ORGANIC LIGANDS FOR SURFACE FUNCTIONALIZATION | PURDUE RESEARCH FOUNDATION (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180076403-A1 | AMINE-BORANES AS ORGANIC LIGANDS FOR SURFACE FUNCTIONALIZATION | PURDUE RESEARCH FOUNDATION (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180051040-A1 | AMINE-BORANES BEARING BORANE-INTOLERANT FUNCTIONALITIES | PURDUE RESEARCH FOUNDATION (US) | 2018-02-22 | — | — | US | disclosed |
| EP-1025090-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2000-11-08 | — | — | EP | disclosed |
| EP-1025090-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2000-08-09 | — | — | EP | disclosed |
| EP-0906103-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-07 | — | — | EP | disclosed |
| EP-0906103-A4 | — | — | 1999-04-07 | — | — | EP | disclosed |
| WO-1999015508-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-01 | — | — | WO | disclosed |
| US-5763461-A | ANTIPICORNAVIRAL AGENTS | SANOFI (FR) | 1998-06-09 | — | — | US | disclosed |
| WO-1997024124-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
| US-5618821-A | VIRICIDES, PICORNAVIRUS | SANOFI, S.A. (FR) | 1997-04-08 | — | — | US | disclosed |
| WO-1995031438-A1 | THERAPEUTIC PHENOXYALKYLHETEROCYCLES | SANOFI WINTHROP, INC. (US) | 1995-11-23 | — | — | WO | disclosed |
| US-4374840-A | TREATMENT OF ANGINA, HYPERTENSION AND ARRHYTHMIA | KOWA COMPANY, LTD. (JP) | 1983-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378744-A1 | COMPOUNDS FOR TREATING PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) MEDIATED DISEASES OR CONDITIONS | PPARG, PPARA, PPARD | CYP1A2 451/4885CYP2C19 807/4885CXCR4 667/4885 |
| US-20180244698-A1 | AMINE-BORANES BEARING BORANE-INTOLERANT FUNCTIONALITIES | TAAR1, NOS2, NOS1 | CYP1A2 945/4885CYP2C19 1124/4885CXCR4 1282/4885 |
| US-20180051040-A1 | AMINE-BORANES BEARING BORANE-INTOLERANT FUNCTIONALITIES | TAAR1, NOS2, NOS1 | CYP1A2 945/4885CYP2C19 1124/4885CXCR4 1282/4885 |
| US-20210069337-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | ITGAV, ITGA5, ITGB5 | CYP1A2 4876/4885CYP2C19 4839/4885CXCR4 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.